The South Australian plant is at the centre of debate over whether a $672 million takeover of the entire business can proceed ...

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on ...

Tariffs increase operational costs by raising prices for raw materials, APIs, and finished drugs, complicating logistics and ...

Vaccine manufacturing is challenged by stringent global regulations, essential for ensuring safety and efficacy, with ...

Clawbacks for the 2024 hospital pharmaceutical budget came in marginally lower than 2023’s critical levels, remaining at an ...

Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...

Sun Pharma considers expanding its US manufacturing footprint amid tariffs. Focus on UNLOXCYT launch and ILUMYA filing.

Clever Culture is bringing automation to pharma microbiology, with its AI tech now used by global heavyweights such as ...

Sun Pharmas CEO discusses potential expansion of its US manufacturing amid tariff challenges, focusing on localised ...

Mochida Pharmaceutical (TSE:4534) reported a net profit margin of 5.7%, up from 4.3% a year earlier, with earnings surging 36.5% over the past year. Despite this progress, shares currently trade at ¥3 ...

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...